Traders Buy Shares of Zoetis (ZTS) on Weakness

Investors purchased shares of Zoetis Inc. (NYSE:ZTS) on weakness during trading on Monday. $75.99 million flowed into the stock on the tick-up and $34.69 million flowed out of the stock on the tick-down, for a money net flow of $41.30 million into the stock. Of all stocks tracked, Zoetis had the 32nd highest net in-flow for the day. Zoetis traded down ($1.28) for the day and closed at $71.02

ZTS has been the subject of several recent research reports. Zacks Investment Research downgraded Zoetis from a “buy” rating to a “hold” rating in a report on Wednesday, November 1st. Jefferies Group reaffirmed a “buy” rating on shares of Zoetis in a report on Friday, November 10th. Stifel Nicolaus reissued a “buy” rating and issued a $65.00 target price on shares of Zoetis in a report on Friday, September 1st. Cantor Fitzgerald set a $75.00 target price on Zoetis and gave the company a “buy” rating in a report on Monday, August 14th. Finally, BidaskClub raised Zoetis from a “sell” rating to a “hold” rating in a report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $68.24.

The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The company has a market capitalization of $35,230.95, a price-to-earnings ratio of 33.17, a P/E/G ratio of 2.17 and a beta of 1.06.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 2nd. The company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.02. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. Zoetis’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.52 earnings per share. sell-side analysts anticipate that Zoetis Inc. will post 2.37 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Thursday, November 9th were paid a dividend of $0.105 per share. This represents a $0.42 annualized dividend and a dividend yield of 0.59%. The ex-dividend date was Wednesday, November 8th. Zoetis’s dividend payout ratio (DPR) is presently 22.11%.

Several large investors have recently added to or reduced their stakes in ZTS. Northwestern Mutual Wealth Management Co. raised its stake in shares of Zoetis by 16.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 1,598 shares of the company’s stock worth $100,000 after buying an additional 230 shares during the last quarter. Steward Partners Investment Advisory LLC acquired a new position in shares of Zoetis during the 3rd quarter worth $114,000. Harfst & Associates Inc. raised its stake in shares of Zoetis by 16.1% during the 2nd quarter. Harfst & Associates Inc. now owns 1,878 shares of the company’s stock worth $117,000 after buying an additional 260 shares during the last quarter. Almanack Investment Partners LLC. acquired a new position in shares of Zoetis during the 2nd quarter worth $119,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in shares of Zoetis by 251.9% during the 3rd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,900 shares of the company’s stock worth $121,000 after buying an additional 1,360 shares during the last quarter. 93.33% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.com-unik.info/2017/12/04/traders-buy-shares-of-zoetis-zts-on-weakness.html.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

What are top analysts saying about Zoetis Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zoetis Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit